Will Paxlovid access mirror vaccine inequity in developing nations?

Question

Accepted Answer

Paxlovid Access May Mirror Vaccine Inequity in Developing Nations

Consumer advocacy group Public Citizen has expressed significant concern that access to Pfizer's new COVID-19 pill, Paxlovid, could replicate the inequities seen in global vaccine distribution. The group has urged Pfizer to allocate at least two-thirds of its 2022 supply of Paxlovid to developing countries at a reasonable price, highlighting the potential for a repeat of the vaccine access challenges. This advocacy effort is anticipated to be a sustained campaign throughout the year, focusing on mitigating disparities in medicine access.
Concerns Over Supply and Distribution

Pfizer's Paxlovid has demonstrated a substantial efficacy in clinical trials, reducing hospitalisations in high-risk patients by approximately 90%. However, the short-term supply remains critically limited. Pfizer projects the capacity to produce 120 million treatment courses in 2022, which falls considerably short of the estimated global market demand of 250 million courses for antiviral pills in the same year. This scarcity, coupled with substantial pre-purchase agreements, such as the United States' commitment to acquire 20 million courses for over $10.5 billion, raises concerns about availability for lower-income nations.
Limited Generic Availability in the Near Term

While Pfizer has indicated it will permit generic manufacturers to produce Paxlovid for low- and middle-income countries, which collectively represent 48% of the global population, significant contributions from these manufacturers are not expected until 2023. Public Citizen has called for Pfizer to actively accelerate the entry of generic alternatives by providing technical assistance and sharing regulatory information. Furthermore, the group advocates for an expansion of the number of countries where these generics can be distributed, aiming to broaden access beyond initial limitations.
Financial Projections and Access Models

Pfizer anticipates substantial revenue in 2022, exceeding $100 billion, with a significant portion derived from Paxlovid and its COVID-19 vaccine. The company has not yet disclosed specific details regarding the volume of Paxlovid sales to low- and middle-income countries through its tiered pricing system, which differentiates costs based on a country's income level. The current model, relying heavily on future generic production for widespread availability in developing nations, is a key point of contention for advocacy groups concerned about immediate access.

Reading history

Hide →

This history is cleared when the page is closed.

Will Paxlovid access mirror vaccine inequity in developing nations?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends